Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Diana Bharucha-Goebel is active.

Publication


Featured researches published by Diana Bharucha-Goebel.


Neurology | 2013

Severe congenital RYR1-associated myopathy: The expanding clinicopathologic and genetic spectrum

Diana Bharucha-Goebel; Mariarita Santi; L. Medne; Kristin Zukosky; J. Dastgir; Perry B. Shieh; Thomas L. Winder; Gihan Tennekoon; Richard S. Finkel; James J. Dowling; Nicole Monnier; Carsten G. Bönnemann

Objective: To report a series of 11 patients on the severe end of the spectrum of ryanodine receptor 1 (RYR1) gene–related myopathy, in order to expand the clinical, histologic, and genetic heterogeneity associated with this group of patients. Methods: Eleven patients evaluated in the neonatal period with severe neonatal-onset RYR1-associated myopathy confirmed by genetic testing were ascertained. Clinical features, molecular testing results, muscle imaging, and muscle histology are reviewed. Results: Clinical features associated with the severe neonatal presentation of RYR1-associated myopathy included decreased fetal movement, hypotonia, poor feeding, respiratory involvement, arthrogryposis, and ophthalmoplegia in 3 patients, and femur fractures or hip dislocation at birth. Four patients had dominant RYR1 mutations, and 7 had recessive RYR1 mutations. One patient had a cleft palate, and another a congenital rigid spine phenotype—findings not previously described in the literature in patients with early-onset RYR1 mutations. Six patients who underwent muscle ultrasound showed relative sparing of the rectus femoris muscle. Histologically, all patients with dominant mutations had classic central cores on muscle biopsy. Patients with recessive mutations showed great histologic heterogeneity, including fibrosis, variation in fiber size, skewed fiber typing, very small fibers, and nuclear internalization with or without ill-defined cores. Conclusions: This series confirms and expands the clinical and histologic variability associated with severe congenital RYR1-associated myopathy. Both dominant and recessive mutations of the RYR1 gene can result in a severe neonatal-onset phenotype, but more clinical and histologic heterogeneity has been seen in those with recessive RYR1 gene mutations. Central cores are not obligatory histologic features in recessive RYR1 mutations. Sparing of the rectus femoris muscle on imaging should prompt evaluation for RYR1-associated myopathy in the appropriate clinical context.


Acta Neuropathologica | 2017

Dihydropyridine receptor (DHPR, CACNA1S) congenital myopathy

Vanessa Schartner; Norma B. Romero; Sandra Donkervoort; Susan Treves; P. Munot; Tyler Mark Pierson; Ivana Dabaj; Edoardo Malfatti; I. Zaharieva; Francesco Zorzato; Osorio Abath Neto; Guy Brochier; Xavière Lornage; Bruno Eymard; A.L. Taratuto; Johann Böhm; Hernan D. Gonorazky; Leigh Ramos-Platt; L. Feng; Rahul Phadke; Diana Bharucha-Goebel; Charlotte J. Sumner; Mai Thao Bui; Emmanuelle Lacène; Maud Beuvin; Clémence Labasse; Nicolas Dondaine; Raphaël Schneider; Julie D. Thompson; Anne Boland

Muscle contraction upon nerve stimulation relies on excitation–contraction coupling (ECC) to promote the rapid and generalized release of calcium within myofibers. In skeletal muscle, ECC is performed by the direct coupling of a voltage-gated L-type Ca2+ channel (dihydropyridine receptor; DHPR) located on the T-tubule with a Ca2+ release channel (ryanodine receptor; RYR1) on the sarcoplasmic reticulum (SR) component of the triad. Here, we characterize a novel class of congenital myopathy at the morphological, molecular, and functional levels. We describe a cohort of 11 patients from 7 families presenting with perinatal hypotonia, severe axial and generalized weakness. Ophthalmoplegia is present in four patients. The analysis of muscle biopsies demonstrated a characteristic intermyofibrillar network due to SR dilatation, internal nuclei, and areas of myofibrillar disorganization in some samples. Exome sequencing revealed ten recessive or dominant mutations in CACNA1S (Cav1.1), the pore-forming subunit of DHPR in skeletal muscle. Both recessive and dominant mutations correlated with a consistent phenotype, a decrease in protein level, and with a major impairment of Ca2+ release induced by depolarization in cultured myotubes. While dominant CACNA1S mutations were previously linked to malignant hyperthermia susceptibility or hypokalemic periodic paralysis, our findings strengthen the importance of DHPR for perinatal muscle function in human. These data also highlight CACNA1S and ECC as therapeutic targets for the development of treatments that may be facilitated by the previous knowledge accumulated on DHPR.


Science Signaling | 2016

Peripheral motor neuropathy is associated with defective kinase regulation of the KCC3 cotransporter

Kristopher T. Kahle; Bianca Flores; Diana Bharucha-Goebel; Jinwei Zhang; Sandra Donkervoort; Madhuri Hegde; Gulnaz Begum; Daniel Duran; Bo Liang; Dandan Sun; Carsten G. Bönnemann; Eric Delpire

Evaluation of a patient with peripheral motor weakness reveals a key role for phosphorylation-dependent regulation of the transporter KCC3 in the peripheral nervous system. Neuropathic KCC3 activity Clinical presentation of disease by patients can lead to profoundly important discoveries about basic biology. In this case, a child with progressive, early-onset, motor neuropathy resulting in profound disability revealed a key role for the phosphorylation-mediated regulation of the K+-Cl− transporter KCC3 in the peripheral nervous system. Kahle et al. discovered a point mutation in the gene encoding KCC3 in the patient that prevented the transporter from being inhibited through phosphorylation and resulted in its constitutive activation. Mice expressing KCC3 with the same mutation had increased transporter activity and impaired locomotor function, suggesting that the normal function of peripheral neurons depends on the regulation of KCC3 function. Using exome sequencing, we identified a de novo mutation (c.2971A>G; T991A) in SLC12A6, the gene encoding the K+-Cl− cotransporter KCC3, in a patient with an early-onset, progressive, and severe peripheral neuropathy primarily affecting motor neurons. Normally, the WNK kinase–dependent phosphorylation of T991 tonically inhibits KCC3; however, cell swelling triggers Thr991 dephosphorylation to activate the transporter and restore cell volume. KCC3 T991A mutation in patient cells abolished Thr991 phosphorylation, resulted in constitutive KCC3 activity, and compromised cell volume homeostasis. KCC3T991A/T991A mutant mice exhibited constitutive KCC3 activity and recapitulated aspects of the clinical, electrophysiological, and histopathological findings of the patient. These results suggest that the function of the peripheral nervous system depends on finely tuned, kinase-regulated KCC3 activity and implicate abnormal cell volume homeostasis as a previously unreported mechanism of axonal degeneration.


Neurology | 2015

Intrafamilial variability in GMPPB-associated dystroglycanopathy: Broadening of the phenotype

Diana Bharucha-Goebel; Erin Neil; Sandra Donkervoort; J. Dastgir; Edythe Wiggs; Thomas L. Winder; Steven A. Moore; Susan T. Iannaccone; Carsten G. Bönnemann

Dystroglycanopathies are characterized by deficient O-mannosyl glycosylation of α-dystroglycan (αDG) and represent an expanding genetically, biochemically, and clinically heterogeneous group of muscular dystrophies. Currently, there are 18 known genes leading to forms of α-dystroglycan–related dystrophy (αDG-RD), ranging in severity from a Walker-Warburg phenotype with severe brain malformations and hypotonia to milder childhood- or adult-onset limb-girdle muscular dystrophy (LGMD) phenotypes with or without intellectual disability.1,2


Neurology Genetics | 2016

The Clinical Outcome Study for dysferlinopathy: An international multicenter study

Elizabeth Harris; Catherine L. Bladen; Anna Mayhew; M. James; Karen Bettinson; Ursula R Moore; Fiona E. Smith; Laura E. Rufibach; Avital Cnaan; Diana Bharucha-Goebel; Andrew M. Blamire; Elena Bravver; Pierre G. Carlier; John W. Day; Jordi Díaz-Manera; Michelle Eagle; Ulrike Grieben; Matthew Harms; Kristi J. Jones; Hanns Lochmüller; Madoka Mori-Yoshimura; Carmen Paradas; Elena Pegoraro; Alan Pestronk; Emmanuelle Salort-Campana; Olivia Schreiber-Katz; Claudio Semplicini; Simone Spuler; Tanya Stojkovic; Volker Straub

Objective: To describe the baseline clinical and functional characteristics of an international cohort of 193 patients with dysferlinopathy. Methods: The Clinical Outcome Study for dysferlinopathy (COS) is an international multicenter study of this disease, evaluating patients with genetically confirmed dysferlinopathy over 3 years. We present a cross-sectional analysis of 193 patients derived from their baseline clinical and functional assessments. Results: There is a high degree of variability in disease onset, pattern of weakness, and rate of progression. No factor, such as mutation class, protein expression, or age at onset, accounted for this variability. Among patients with clinical diagnoses of Miyoshi myopathy or limb-girdle muscular dystrophy, clinical presentation and examination was not strikingly different. Respiratory impairment and cardiac dysfunction were observed in a minority of patients. A substantial delay in diagnosis was previously common but has been steadily reducing, suggesting increasing awareness of dysferlinopathies. Conclusions: These findings highlight crucial issues to be addressed for both optimizing clinical care and planning therapeutic trials in dysferlinopathy. This ongoing longitudinal study will provide an opportunity to further understand patterns and variability in disease progression and form the basis for trial design.


Journal of Child Neurology | 2016

Novel De Novo Mutations in KIF1A as a Cause of Hereditary Spastic Paraplegia With Progressive Central Nervous System Involvement

Leslie Hotchkiss; Sandra Donkervoort; M. Leach; Payam Mohassel; Diana Bharucha-Goebel; Nathaniel Bradley; David Nguyen; Ying Hu; Juliana Gurgel-Giannetti; Carsten G. Bönnemann

Hereditary spastic paraplegias are a clinically and genetically heterogeneous group of disorders characterized by lower extremity spasticity and weakness. Recently, the first de novo mutations in KIF1A were identified in patients with an early-onset severe form of complicated hereditary spastic paraplegia. We report two additional patients with novel de novo mutations in KIF1A, hereby expanding the genetic spectrum of KIF1A-related hereditary spastic paraplegia. Both children presented with spastic paraplegia and additional findings of optic nerve atrophy, structural brain abnormalities, peripheral neuropathy, cognitive/language impairment, and never achieved ambulation. In particular, we highlight the progressive nature of cerebellar involvement as captured on sequential magnetic resonance images (MRIs), thus linking the neurodegenerative and spastic paraplegia phenotypes. Exome sequencing in patient 1 and patient 2 identified novel heterozygous missense mutations in KIF1A at c.902G>A (p.R307Q) and c.595G>A (p.G199 R), respectively. Therefore, our report contributes to expanding the genotypic and phenotypic spectrum of hereditary spastic paraplegia caused by mutations in KIF1A.


Annals of Neurology | 2018

Congenital Titinopathy: Comprehensive characterization and pathogenic insights: Congenital Titinopathy

Emily C. Oates; Kristi J. Jones; Sandra Donkervoort; Amanda Charlton; Susan Brammah; John E. Smith; James S. Ware; Kyle S. Yau; Lindsay C. Swanson; Nicola Whiffin; Anthony J. Peduto; Adam Bournazos; Leigh B. Waddell; Michelle A. Farrar; Hugo Sampaio; Hooi Ling Teoh; Phillipa Lamont; David Mowat; Robin B. Fitzsimons; Alastair Corbett; Monique M. Ryan; Gina L. O'Grady; Sarah A. Sandaradura; Roula Ghaoui; Himanshu Joshi; Jamie L. Marshall; Melinda A. Nolan; Simranpreet Kaur; Ana Töpf; Elizabeth Harris

Comprehensive clinical characterization of congenital titinopathy to facilitate diagnosis and management of this important emerging disorder.


Science Translational Medicine | 2018

PIEZO2 mediates injury-induced tactile pain in mice and humans

Marcin Szczot; Jaquette Liljencrantz; Nima Ghitani; Arnab Barik; Ruby M. Lam; James H. Thompson; Diana Bharucha-Goebel; Dimah Saade; Aaron Necaise; Sandra Donkervoort; A. Reghan Foley; Taylor Gordon; Laura K. Case; M. Catherine Bushnell; Carsten G. Bönnemann; Alexander T. Chesler

The stretch-gated ion channel PIEZO2 is required for inflammation-induced tactile allodynia. Understanding pain sensitization Inflammation or nerve injury can alter tactile sensation, making a gentle touch perceived as painful. The molecular mechanisms mediating this alteration in sensation, called mechanical allodynia, are not completely understood. Murthy et al. and Szczot et al. found that PIEZO2 ion channels expressed in sensory neurons are required for the development of mechanical allodynia in mice and humans. The authors independently reached this conclusion using different animal models. Szczot et al. extended the discovery to humans, showing that PIEZO2 loss of function resulted in failure to develop mechanical allodynia. These two studies suggest that local inhibition of PIEZO2 ion channels might be effective for treating mechanical allodynia. Tissue injury and inflammation markedly alter touch perception, making normally innocuous sensations become intensely painful. Although this sensory distortion, known as tactile allodynia, is one of the most common types of pain, the mechanism by which gentle mechanical stimulation becomes unpleasant remains enigmatic. The stretch-gated ion channel PIEZO2 has been shown to mediate light touch, vibration detection, and proprioception. However, the role of this ion channel in nociception and pain has not been resolved. Here, we examined the importance of Piezo2 in the cellular representation of mechanosensation using in vivo imaging in mice. Piezo2-knockout neurons were completely insensitive to gentle dynamic touch but still responded robustly to noxious pinch. During inflammation and after injury, Piezo2 remained essential for detection of gentle mechanical stimuli. We hypothesized that loss of PIEZO2 might eliminate tactile allodynia in humans. Our results show that individuals with loss-of-function mutations in PIEZO2 completely failed to develop sensitization and painful reactions to touch after skin inflammation. These findings provide insight into the basis for tactile allodynia, identify the PIEZO2 mechanoreceptor as an essential mediator of touch under inflammatory conditions, and suggest that this ion channel might be targeted for treating tactile allodynia.


Neuromuscular Disorders | 2017

Common and variable clinical, histological, and imaging findings of recessive RYR1-related centronuclear myopathy patients.

Osorio Abath Neto; Cristiane de Araújo Martins Moreno; Edoardo Malfatti; Sandra Donkervoort; Johann Böhm; júlio Brandão Guimarães; A. Reghan Foley; Payam Mohassel; J. Dastgir; Diana Bharucha-Goebel; Soledad Monges; Fabiana Lubieniecki; James J. Collins; L. Medne; Mariarita Santi; Sabrina W. Yum; Brenda Banwell; Emmanuelle Salort-Campana; John Rendu; Julien Fauré; Uluç Yiş; Bruno Eymard; Chrystel Cheraud; Raphaël Schneider; Julie D. Thompson; Xavière Lornage; Lilia Mesrob; Doris Lechner; Anne Boland; Jean-François Deleuze

Mutations in RYR1 give rise to diverse skeletal muscle phenotypes, ranging from classical central core disease to susceptibility to malignant hyperthermia. Next-generation sequencing has recently shown that RYR1 is implicated in a wide variety of additional myopathies, including centronuclear myopathy. In this work, we established an international cohort of 21 patients from 18 families with autosomal recessive RYR1-related centronuclear myopathy, to better define the clinical, imaging, and histological spectrum of this disorder. Early onset of symptoms with hypotonia, motor developmental delay, proximal muscle weakness, and a stable course were common clinical features in the cohort. Ptosis and/or ophthalmoparesis, facial weakness, thoracic deformities, and spinal involvement were also frequent but variable. A common imaging pattern consisted of selective involvement of the vastus lateralis, adductor magnus, and biceps brachii in comparison to adjacent muscles. In addition to a variable prominence of central nuclei, muscle biopsy from 20 patients showed type 1 fiber predominance and a wide range of intermyofibrillary architecture abnormalities. All families harbored compound heterozygous mutations, most commonly a truncating mutation combined with a missense mutation. This work expands the phenotypic characterization of patients with recessive RYR1-related centronuclear myopathy by highlighting common and variable clinical, histological, and imaging findings in these patients.


Journal of Neurology, Neurosurgery, and Psychiatry | 2018

Teenage exercise is associated with earlier symptom onset in dysferlinopathy: a retrospective cohort study

Ursula R Moore; M. Jacobs; Roberto Fernández-Torrón; Jiji Jang; M. James; Anna Mayhew; Laura E. Rufibach; Plavi Mittal; Michelle Eagle; Avital Cnaan; Pierre G. Carlier; Andrew M. Blamire; H. Hilsden; Hanns Lochmüller; Ulrike Grieben; Simone Spuler; Carolina Tesi Rocha; John W. Day; Kristi J. Jones; Diana Bharucha-Goebel; Emmanuelle Salort-Campana; Matthew B. Harms; Alan Pestronk; Sabine Krause; Olivia Schreiber-Katz; Maggie C. Walter; Carmen Paradas; Jean-Yves Hogrel; Tanya Stojkovic; Shin'ichi Takeda

Dysferlinopathy, an autosomal recessive muscular dystrophy caused by DYSF mutations, demonstrates a variable phenotype and progression rate, with symptom onset ranging from first to eighth decade and some patients requiring wheelchairs for mobility within 10 years, with others remaining minimally affected.1 Dysferlinopathy populations have previously been described as having an unusually high level of presymptomatic sporting ability.2 We hypothesised that this activity could be related to subsequent disease progression and investigated the hypothesis using data from the Jain Foundation’s Clinical Outcomes Study (COS) of 202 patients with dysferlinopathy.1 Data were used from 182 of the 202 patients enrolled in the Jain COS; 10 dropped out and did not give permission to use their data and 10 did not fully complete the exercise questionnaire. The questionnaire used in the screening visits (online supplementary information) between 6 November 2012 and 19 March 2015 asked about the type, level and frequency of all physical activity prior to symptom onset. Self-reported age of first symptoms, first wheelchair use and full-time wheelchair use was taken from screening questionnaires. Exercises were classified based on metabolic equivalents (METs) as moderate (MET 3–6) or vigorous (MET >6) (online supplementary table 1).3 Participants were coded, based on the maximum frequency of activity reported between ages 10 and 18 years, as 0—no physical activity; 1—vigorous activity occasionally/monthly, or moderate activity once weekly; 2— moderate activity multiple times per week or vigorous activity once weekly; and 3—vigorous activity multiple times per week. ### Supplementary file 1 [jnnp-2017-317329-SP1.pdf] ### Statistical analysis Age of symptom onset was compared by analysis of variance (ANOVA) with least squares means for individual group differences. Risk of symptom onset, occasional wheelchair use and full-time wheelchair requirement over time were compared for exercise groups 1, 2 and 3 against group 0 using Cox proportional hazards regression. Proportional hazards assumption was violated …

Collaboration


Dive into the Diana Bharucha-Goebel's collaboration.

Top Co-Authors

Avatar

Carsten G. Bönnemann

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Sandra Donkervoort

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

A. Reghan Foley

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

M. Waite

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Payam Mohassel

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Ying Hu

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

J. Dastgir

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

M. Jain

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

M. Leach

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Kristi J. Jones

Children's Hospital at Westmead

View shared research outputs
Researchain Logo
Decentralizing Knowledge